Neuroprotection in diabetic retinopathy
- PMID: 22581259
- DOI: 10.1007/s11892-012-0284-5
Neuroprotection in diabetic retinopathy
Abstract
Diabetic retinopathy (DR) has been considered to be a microcirculatory disease of the retina. However, there is emerging evidence to suggest that retinal neurodegeneration is an early event in the pathogenesis of DR, which may antedate, and also participates in, the microcirculatory abnormalities that occur in DR. Therefore, the study of the underlying mechanisms that lead to neurodegeneration will be essential for identifying new therapeutic targets in the early stages of DR. Elevated levels of glutamate, oxidative stress, the overexpression of the renin-angiotensin system and the upregulation of RAGE play an essential role in the retinal neurodegeneration induced by diabetes. Finally, the balance between the neurotoxic and neuroprotective factors is crucial in determining the survival of retinal neurons. In this review we will focus on neurotrophic factors already synthesized by the retina in physiological conditions as a new therapy strategy for neuroprotection.
Similar articles
-
Neurodegeneration in the diabetic eye: new insights and therapeutic perspectives.Trends Endocrinol Metab. 2014 Jan;25(1):23-33. doi: 10.1016/j.tem.2013.09.005. Epub 2013 Nov 1. Trends Endocrinol Metab. 2014. PMID: 24183659 Review.
-
Somatostatin replacement: a new strategy for treating diabetic retinopathy.Curr Med Chem. 2013;20(26):3251-7. doi: 10.2174/09298673113209990024. Curr Med Chem. 2013. PMID: 23745546 Review.
-
Neurodegeneration is an early event in diabetic retinopathy: therapeutic implications.Br J Ophthalmol. 2012 Oct;96(10):1285-90. doi: 10.1136/bjophthalmol-2012-302005. Epub 2012 Aug 11. Br J Ophthalmol. 2012. PMID: 22887976 Review.
-
Plasma angiogenesis and oxidative stress markers in patients with diabetic retinopathy.Biomarkers. 2020 Jul;25(5):397-401. doi: 10.1080/1354750X.2020.1774654. Epub 2020 Jun 12. Biomarkers. 2020. PMID: 32529845
-
Cellular and Molecular Mechanisms of Neuronal Degeneration in Early-Stage Diabetic Retinopathy.Curr Vasc Pharmacol. 2024;22(5):301-315. doi: 10.2174/0115701611272737240426050930. Curr Vasc Pharmacol. 2024. PMID: 38693745 Review.
Cited by
-
Neuropeptides and diabetic retinopathy.Br J Clin Pharmacol. 2013 May;75(5):1189-201. doi: 10.1111/bcp.12003. Br J Clin Pharmacol. 2013. PMID: 23043302 Free PMC article. Review.
-
Abnormalities in glutamate metabolism and excitotoxicity in the retinal diseases.Scientifica (Cairo). 2013;2013:528940. doi: 10.1155/2013/528940. Epub 2013 Dec 9. Scientifica (Cairo). 2013. PMID: 24386591 Free PMC article. Review.
-
CTRP3 is a novel biomarker for diabetic retinopathy and inhibits HGHL-induced VCAM-1 expression in an AMPK-dependent manner.PLoS One. 2017 Jun 20;12(6):e0178253. doi: 10.1371/journal.pone.0178253. eCollection 2017. PLoS One. 2017. PMID: 28632765 Free PMC article.
-
Protective effects of Scoparia dulcis L. extract on high glucose-induced injury in human retinal pigment epithelial cells.Front Nutr. 2023 Mar 30;10:1085248. doi: 10.3389/fnut.2023.1085248. eCollection 2023. Front Nutr. 2023. PMID: 37139437 Free PMC article.
-
Molecular Implications of the PPARs in the Diabetic Eye.PPAR Res. 2013;2013:686525. doi: 10.1155/2013/686525. Epub 2013 Feb 4. PPAR Res. 2013. PMID: 23431285 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical